Wittlich

Researchers are conducting a prospective, non-interventional observational study to understand how patients aged 6 years and older with atopic dermatitis (AD) respond to treatment with dupilumab in everyday medical practice. The study aims to characterize these patients by examining their medical history, demographic and disease-related features, associated allergic conditions, other type 2 inflammation diseases, and their past and current treatments. The study will also assess the long-term effectiveness and safety of dupilumab over two years, focusing on disease control and quality of life.